卡托普利、安体舒通、生脉在慢性肺心病合并右心衰竭治疗中的效果  

EFFICACY OF CAPTOPRIL, SPIRONOLACTONE AND SHENGMAI IN THE TREATMENT OF CHRONIC PULMONARY HEART DISEASE COMPLICATED WITH RIGHT HEART FAILURE

作　　者：邓烨 黄海宁[1] Deng Ye;Huang Haining(Department of Cardiology,Huizhou First People's Hospital,Guangdong Province,516003,China)

机构地区：[1]惠州市第一人民医院心血管内科

出　　处：《现代电生理学杂志》2019年第3期151-154,共4页Journal of Modern Electrophysiology

摘　　要：目的:探讨卡托普利、安体舒通、生脉在慢性肺心病合并右心衰竭中的临床效果。方法:选择2017年4月至2019年4月于惠州市第一人民医院心血管内科治疗的慢性肺心病合并右心衰竭患者120例作为研究对象,性别不限,年龄46~77岁,根据随机数字表法分为研究组和常规治疗组,每组60例。常规治疗组接受常规治疗,包括强心和利尿治疗,研究组在常规治疗的基础上接受卡托普利、安体舒通、生脉治疗。比较两组患者的治疗效果及治疗前、后QRS波时限。结果:研究组患者的总有效率高于常规治疗组(95.0%%比80.0%),差异有统计学意义(P<0.05)。治疗后研究组心电图QRS时限为(0.09±0.03)s,常规治疗组为(0.18±0.05)s,差异具有统计学意义(t=3.47,P<0.05)。两组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:卡托普利、安体舒通、生脉治疗慢性肺心病合并右心衰患者临床效果确切,对患者心功能具有改善作用。Objective: To investigate the efficacy of captopril,spironolactone and shengmai in the treatment of chronic pulmonary heart disease complicated with right heart failure.Methods: A total of 120 patients with chronic pulmonary heart disease complicated with right heart failure,both sexes,46-77 years old,from April 2017 to April 2019 in Huizhou First People's Hospital,were randomly divided into study group and conventional treatment group according to random number table method,60 cases in each group.The patients received conventional treatment in conventional treatment group,including cardiotonic and diuretic treatment,captopril, spironolactone and shengmai treatment on the basis of conventional treatment in study group.The therapeutic effect and QRS duration before and after the treatment were compared between the two groups.Results: The total effective rate was higher in study group than that in conventional treatment group (95.0% vs.80.0%,P <0.05).The QRS duration of electrocardiogram was (0.09±0.03) s in study group and (0.18±0.05) s in conventional treatment group after the treatment (t =3.47,P <0.05).There was no significant difference for the incidence rate of adverse reactions between the two groups (P >0.05).Conclusion: Captopril,spironolactone and shengmai are effective in the treatment of chronic pulmonary heart disease complicated with right heart failure,and can improve the cardiac function of patients.

关 键 词：肺心病 心力衰竭 束支传导阻滞 卡托普利 安体舒通 生脉 

分 类 号：R541[医药卫生—心血管疾病]